Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Tet2-mediated macrophage activation promotes liver regeneration

View through CrossRef
Abstract Objective Macrophages are predominant immune cells that secret IL-6 and HGF to promote liver regeneration after liver resection. Ten-eleven translocation- 2 (Tet2) DNA dioxygenase regulates the secretion of pro-inflammatory factors in macrophages. In this study, we explored the role of Tet2 in macrophages and its function independent of its enzymatic activity in liver regeneration. Methods A 70% partial hepatectomy mice model was established. Enzyme-linked immunosorbent assays, quantitative reverse transcription-polymerase chain reaction, western blotting, immunofluorescences, and flow cytometry were performed to explore the infiltration and phenotypes of immune cells in mice models. Molecular dynamics simulations were carried out to study the interaction of Tet2 with Stat1. Results We found Tet2 in macrophages negatively regulates liver regeneration in the partial hepatectomy mice model. In mechanism, Tet2 interacts with Stat1 to inhibit the expressions of proinflammatory factors and suppress liver regeneration. Tet2 inhibitor BC339 attenuated the interaction of Stat1 and Tet2, enhanced Stat1 phosphorylation, and promoted hepatocyte proliferation. Notably, Tet2 also directly affected hepatocyte proliferation, independent of the IL-6-Stat3 signaling pathway. Conclusion Tet2 in macrophages negatively regulates liver regeneration via interacting with Stat1. Our results suggest that specific targeting Tet2 in macrophages promotes the recovery of liver function after hepatectomy. Keywords Macrophage, Liver regeneration, partial hepatectomy, Tet2.
Title: Tet2-mediated macrophage activation promotes liver regeneration
Description:
Abstract Objective Macrophages are predominant immune cells that secret IL-6 and HGF to promote liver regeneration after liver resection.
Ten-eleven translocation- 2 (Tet2) DNA dioxygenase regulates the secretion of pro-inflammatory factors in macrophages.
In this study, we explored the role of Tet2 in macrophages and its function independent of its enzymatic activity in liver regeneration.
Methods A 70% partial hepatectomy mice model was established.
Enzyme-linked immunosorbent assays, quantitative reverse transcription-polymerase chain reaction, western blotting, immunofluorescences, and flow cytometry were performed to explore the infiltration and phenotypes of immune cells in mice models.
Molecular dynamics simulations were carried out to study the interaction of Tet2 with Stat1.
Results We found Tet2 in macrophages negatively regulates liver regeneration in the partial hepatectomy mice model.
In mechanism, Tet2 interacts with Stat1 to inhibit the expressions of proinflammatory factors and suppress liver regeneration.
Tet2 inhibitor BC339 attenuated the interaction of Stat1 and Tet2, enhanced Stat1 phosphorylation, and promoted hepatocyte proliferation.
Notably, Tet2 also directly affected hepatocyte proliferation, independent of the IL-6-Stat3 signaling pathway.
Conclusion Tet2 in macrophages negatively regulates liver regeneration via interacting with Stat1.
Our results suggest that specific targeting Tet2 in macrophages promotes the recovery of liver function after hepatectomy.
Keywords Macrophage, Liver regeneration, partial hepatectomy, Tet2.

Related Results

D-mannose alleviates chronic periodontitis in rats by regulating the functions of neutrophils
D-mannose alleviates chronic periodontitis in rats by regulating the functions of neutrophils
Abstract Background Periodontitis is a chronic inflammatory disease without effective treatment. Nowadays, the critical role of neutrophils in periodontitis is getting bet...
Phylogenetic Analysis of TET2 Gene Variants in Pakistani Acute Myeloid Leukemia Patients
Phylogenetic Analysis of TET2 Gene Variants in Pakistani Acute Myeloid Leukemia Patients
Abstract Background Acute myeloid leukemia (AML) is a heterogeneous malignancy caused by the proliferation of neoplastic myeloid progenit...
Impaired Function of Fancc-/- Immune Cells.
Impaired Function of Fancc-/- Immune Cells.
Abstract Abstract 1494 Fanconi anemia (FA) is a genetic disorder characterized by bone marrow (BM) failure, developmental defects and cancer predispos...
Abstract 1427: Sensitizing HL60 acute myeloid leukemia cells to decitabine with pterostilbene
Abstract 1427: Sensitizing HL60 acute myeloid leukemia cells to decitabine with pterostilbene
Abstract Introduction. Decitabine (DAC), is a DNA hypomethylating agent that has been shown to be potent towards leukemia cells at low doses. However, many patients ...
Dynamics of Mutations in Patients with ET Treated with Imetelstat
Dynamics of Mutations in Patients with ET Treated with Imetelstat
Abstract Background: Imetelstat, a first in class specific telomerase inhibitor, induced hematologic responses in all patients (pts) with essential thrombocythemia (...
Abstract 1570: Macrophage mediated cell-kill evasion by human prostate cancer cells
Abstract 1570: Macrophage mediated cell-kill evasion by human prostate cancer cells
Abstract Macrophages can adopt a cytotoxic M1 phenotype which can eliminate cancer cells. However, despite the presence of macrophages in the prostate, prostate canc...
MR elastography‐based liver fibrosis correlates with liver events in nonalcoholic fatty liver patients: A multicenter study
MR elastography‐based liver fibrosis correlates with liver events in nonalcoholic fatty liver patients: A multicenter study
AbstractBackground & AimsLiver fibrosis assessed by liver biopsy is predictive of clinical liver events in patients with nonalcoholic fatty liver disease (NAFLD). Magnetic reso...
Abstract 118: Interleukin 4 And 13 Signaling In Macrophages Regulates Neonatal Cardiac Regeneration
Abstract 118: Interleukin 4 And 13 Signaling In Macrophages Regulates Neonatal Cardiac Regeneration
Introduction: Heart failure (HF) is a prevalent disease, projected to affect over 8 million Americans by 2030. Current therapy partially decreases progression; however,...

Back to Top